Pensionfund Sabic Buys Shares of 4,800 Cencora, Inc. $COR

Pensionfund Sabic purchased a new position in shares of Cencora, Inc. (NYSE:COR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,800 shares of the company’s stock, valued at approximately $1,621,000.

Several other hedge funds and other institutional investors have also modified their holdings of COR. IAG Wealth Partners LLC acquired a new stake in shares of Cencora in the third quarter valued at $30,000. Vermillion & White Wealth Management Group LLC lifted its stake in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares in the last quarter. Cloud Capital Management LLC purchased a new position in Cencora during the 3rd quarter valued at about $31,000. Caitlin John LLC purchased a new position in Cencora during the 3rd quarter valued at about $31,000. Finally, Westside Investment Management Inc. grew its position in Cencora by 200.0% in the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock valued at $33,000 after acquiring an additional 70 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: The acquisition expands Cencora’s Retina Consultants of America platform and strengthens its footprint in the fast-growing eye care market, adding scale and potential cross-selling opportunities for pharma and services. Cencora to buy EyeSouth’s retina business for $1.1 billion
• Positive Sentiment: Analyst and trade coverage frames the deal as a clear add-on to RCA that builds scale in a specialty with high procedure volumes and recurring treatment needs, which could support revenue and margin improvement over time. COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal
• Neutral Sentiment: The transaction is widely reported across outlets (Reuters, Seeking Alpha, Fierce Healthcare), which helps transparency and may accelerate investor re-pricing; details on financing and expected contribution to guidance remain limited. Cencora to buy retina business of EyeSouth Partners for $1.1 billion
• Neutral Sentiment: COR is included in actively managed ETF baskets highlighted by MarketBeat, which can bring incremental demand from fund flows rather than direct company fundamentals. That placement may amplify moves in COR shares as funds trade. Active ETFs Surge Past Passive, and These Are in the Lead (COR)
• Negative Sentiment: Potential near-term negatives include transaction financing, integration costs and execution risk; Cencora already carries a relatively high debt-to-equity ratio, so investors should watch how the deal is funded and whether it materially affects leverage. Conshohocken’s Cencora Prepares for Leadership Change This Summer

Wall Street Analyst Weigh In

A number of analysts have issued reports on COR shares. Morgan Stanley set a $380.00 price target on shares of Cencora in a research note on Tuesday, March 17th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Bank of America cut their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Barclays increased their target price on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Finally, Leerink Partners reissued an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average target price of $403.17.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.38% of the stock is owned by company insiders.

Cencora Price Performance

COR stock opened at $327.12 on Wednesday. The business has a 50 day moving average price of $354.13 and a 200 day moving average price of $340.68. The stock has a market cap of $63.63 billion, a price-to-earnings ratio of 39.32, a PEG ratio of 1.49 and a beta of 0.68. Cencora, Inc. has a fifty-two week low of $265.59 and a fifty-two week high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the prior year, the firm posted $3.73 earnings per share. The firm’s revenue was up 5.5% on a year-over-year basis. Equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio (DPR) is 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.